Vaccinogen raises $10M for work on colon cancer vaccine

Frederick, MD-based Vaccinogen has scored $10 million to fund work on its colon cancer candidate, OncoVax. A Stockholm-based investor group known as The Investment Syndicate put up the money, and Vaccinogen will receive another $70 million in four more payments. Vaccinogen is prepping a confirmatory Phase IIIb pivotal study of the patient-specific vaccine in patients with resectable, Stage 2 colon cancer. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.